IL151987A0 - Nuclear factor kb inducing factor - Google Patents

Nuclear factor kb inducing factor

Info

Publication number
IL151987A0
IL151987A0 IL15198701A IL15198701A IL151987A0 IL 151987 A0 IL151987 A0 IL 151987A0 IL 15198701 A IL15198701 A IL 15198701A IL 15198701 A IL15198701 A IL 15198701A IL 151987 A0 IL151987 A0 IL 151987A0
Authority
IL
Israel
Prior art keywords
nfif
polypeptides
methods
factor
nfkb
Prior art date
Application number
IL15198701A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL151987A0 publication Critical patent/IL151987A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15198701A 2000-03-31 2001-04-02 Nuclear factor kb inducing factor IL151987A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (1)

Publication Number Publication Date
IL151987A0 true IL151987A0 (en) 2003-04-10

Family

ID=26244722

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15198701A IL151987A0 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor
IL151987A IL151987A (en) 2000-03-31 2002-09-29 NUCLEIC ACID ENCODING NUCLEAR FACTOR kb INDUCING FACTOR (nfif), POLYPEPTIDE AND A MEDICAMENT COMPRISING THE SAME
IL198132A IL198132A0 (en) 2000-03-31 2009-04-16 Nuclear factor kb inducing factor

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL151987A IL151987A (en) 2000-03-31 2002-09-29 NUCLEIC ACID ENCODING NUCLEAR FACTOR kb INDUCING FACTOR (nfif), POLYPEPTIDE AND A MEDICAMENT COMPRISING THE SAME
IL198132A IL198132A0 (en) 2000-03-31 2009-04-16 Nuclear factor kb inducing factor

Country Status (15)

Country Link
EP (1) EP1290023B1 (ja)
JP (1) JP4750999B2 (ja)
KR (1) KR100811571B1 (ja)
AT (1) ATE486089T1 (ja)
AU (1) AU4793101A (ja)
CA (1) CA2404688C (ja)
DE (1) DE60143354D1 (ja)
DK (1) DK1290023T3 (ja)
HK (1) HK1053312A1 (ja)
IL (3) IL151987A0 (ja)
MX (1) MXPA02009481A (ja)
NO (1) NO331972B1 (ja)
NZ (1) NZ521786A (ja)
PT (1) PT1290023E (ja)
WO (1) WO2001074900A2 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341091C (en) 1983-10-20 2000-09-05 Masayori Inouye Regulation of gene expression by employing translational inhibition utilizaing mrna interfering complementary rna
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
AU3129993A (en) 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1993023569A1 (en) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
PL179877B1 (pl) 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
JP2000507829A (ja) * 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
JP2002534055A (ja) * 1998-05-14 2002-10-15 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｖ
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
CA2403946A1 (en) * 2000-04-05 2001-10-18 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
JP2004509612A (ja) * 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング

Also Published As

Publication number Publication date
ATE486089T1 (de) 2010-11-15
EP1290023B1 (en) 2010-10-27
IL198132A0 (en) 2011-08-01
DE60143354D1 (de) 2010-12-09
JP4750999B2 (ja) 2011-08-17
NZ521786A (en) 2004-07-30
IL151987A (en) 2010-12-30
WO2001074900A2 (en) 2001-10-11
KR100811571B1 (ko) 2008-03-10
EP1290023A2 (en) 2003-03-12
HK1053312A1 (en) 2003-10-17
NO20024656D0 (no) 2002-09-27
MXPA02009481A (es) 2004-05-14
WO2001074900A3 (en) 2002-05-02
DK1290023T3 (da) 2011-02-14
KR20020087459A (ko) 2002-11-22
PT1290023E (pt) 2011-01-05
CA2404688A1 (en) 2001-10-11
JP2003529360A (ja) 2003-10-07
NO20024656L (no) 2002-11-28
CA2404688C (en) 2012-07-31
NO331972B1 (no) 2012-05-14
WO2001074900A9 (en) 2003-03-06
AU4793101A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
SE9800836D0 (sv) New Compounds
ATE232396T1 (de) Oxydiertes thymosin beta 4
EP1581119A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS FOR INFLAMMATORY BOWEL DISEASE
EP1578347A4 (en) COMPOSITIONS AND METHODS FOR DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNES DISEASES
HUP0200493A2 (en) Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseases
HUP9900560A2 (hu) PPAR-alfa és PPAR-gamma antagonisták alkalmazása X-szindróma kezelésében
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
EP1552298A4 (en) RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
AU4347701A (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DE60233436D1 (de) In der mundhöhle dispergierbare feste pharmazeutische form
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
IL198132A0 (en) Nuclear factor kb inducing factor
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
GB9930075D0 (en) Medicaments
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
DE60221501D1 (de) Bfit (brown fat inducible thioesterase) polypeptide und polynukleotide und ihre verwendung
BR0109721A (pt) Fator de indução do fator kb nuclear
EP0905234A3 (en) Allelic variant of human STAT3
ATE340576T1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit